Being overweight, obese, or diabetic are known risk factors for increasing the incidence and worsening the prognosis of CRC
Tirzepatide (SURMOUNT Trials) Tirzepatides dual-agonist approach produced greater weight reduction than semaglutide in head-to-head comparisons
For additional context on how compounded tirzepatide with B12 supports tolerability throughout treatment, see TRT Nations guide on compounded tirzepatide with B12
CareFirst BlueCross BlueShield is joining forces with Ryse Health, a company that specializes in providing in-person and virtual care for patients with uncontrolled Type 2 diabetes, in hopes of driving better long-term outcomes
Relationship Between Diet, Tinnitus, and Hearing Difficulties
The FLOW study was a RCT testing semaglutide in 3533 patients with T2D and chronic kidney disease